Skip to content

Efficacy of laser therapy in extrimity wart

Efficacy and safety of nd:yag laser therapy with cryotherapy in extremities(hand,foot) wart

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016050127707N1
Enrollment
63
Registered
2016-08-16
Start date
2016-01-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

wart. Anogenital (venereal) warts

Interventions

Intervention 1: The patients with bilateral extrimitie's warts will join to study,and all of their demoghraphic datas and properties(site,diameter) of warts and association are saved . after preparat
yag laser(laser optek) with setting , fluence: 200 j/cm^2 , spot size :3mm, duration:20ms? wave length: 1064 nm. in every session with 3 shots circular guide. all patients follow and evaluate 3 m
Treatment - Other
The patients with bilateral extrimitie's warts will join to study,and all of their demoghraphic datas and properties(site,diameter) of warts and association are saved . after preparation and anesthesi
The patients with bilateral extrimitie's warts will join to study,and all of their demoghraphic datas and properties(site,diameter) of warts and association are saved . after preparation and anesthe
yag laser(laser optek) with setting , fluence: 200 j/cm^2 , spot size :3mm, duration:20ms? wave length: 1064 nm. in every session with 3 shots circular guide. all patients follow and evaluate 3

Sponsors

Shahid Beheshti University of Medical Science-Skin Research Center.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria:bilateral warts on extremities(upper or lower) Exclusion criteria:immunodeficiency state(diabetes mellitus;alcohol abuse) congenital immunodeficiency disorders; hematologic malignancy; drug history of immunnomodulator agent during 4 weeks past; drug history of anti viral agent during 2 weeks past;pregnancy;breast feeding.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Diameter of primary lesion on centimeters. Timepoint: 2weeks. Method of measurement: ruller.

Secondary

MeasureTime frame
Blister and ulser formation. Timepoint: 2 weeks. Method of measurement: physical examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehzad Iranmanesh

Skin Research Center

behzad_ariiana@yahoo.com mgheisari@sbmu.ac.ir+98 21 2676 1435

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026